title: Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible.
abstract: Patient KW, a 36-yr-old male renal transplant recipient, received transplant acceptance-inducing cells (TAICs) as an adjunct immunosuppressive therapy. In the weeks post-transplantation, the patient's conventional immunosuppressive treatment was gradually minimized, such that, from the 21st wk post-transplantation onwards, the patient was stably maintained on tacrolimus monotherapy. Treatment with TAICs was without complication, both at the time of administration and in the four-yr follow-up period. It is concluded that the production and administration of TAICs to recipients of kidney transplants from deceased donors is technically feasible.
authors.affiliation: Department of General and Cardiothoracic Surgery, Laboratory for Transplantation Research, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany. james.hutchinson@cantab.net
authors.forename: James A
authors.initials: JA
authors.lastname: Hutchinson
authors.forename: Felix
authors.initials: F
authors.lastname: Gövert
authors.forename: Paloma
authors.initials: P
authors.lastname: Riquelme
authors.forename: Jan Hinrich
authors.initials: JH
authors.lastname: Bräsen
authors.forename: Beate G
authors.initials: BG
authors.lastname: Brem-Exner
authors.forename: Martina
authors.initials: M
authors.lastname: Matthäi
authors.forename: Maren
authors.initials: M
authors.lastname: Schulze
authors.forename: Lutz
authors.initials: L
authors.lastname: Renders
authors.forename: Ulrich
authors.initials: U
authors.lastname: Kunzendorf
authors.forename: Edward K
authors.initials: EK
authors.lastname: Geissler
authors.forename: Fred
authors.initials: F
authors.lastname: Fändrich
mesh_terms: D000328:Adult; D002102:Cadaver; D064987:Cell- and Tissue-Based Therapy; D005240:Feasibility Studies; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D016559:Tacrolimus / Q000627:therapeutic use; D014019:Tissue Donors; D019172:Transplantation Conditioning; D023001:Transplantation Tolerance / Q000276:immunology*
chemical_list: D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016559:Tacrolimus